Skip to main content
SpringerLink
Log in

Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment

  • Chapter
Tumor Angiogenesis

  • 1810 Accesses

Abstract

Surpassing several setbacks, the clinical development of antiangiogenic agents has accelerated remarkably over the past 3–4 years. As a result, there are currently three direct blockers of the VEGF pathway approved for use in cancer, and two others for age-related wet macular degeneration. Other agents that block the VEGF pathway are currently in advanced stages of clinical development and have shown promising results. With these exciting developments come critical questions regarding the use of these new molecularly targeted agents, alone or in combination with standard cytotoxic or targeted agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ansiaux R, Baudelet C, Jordan BF, Beghein N, Sonveaux P, De Wever J, Martinive P, Gregoire V, Feron O, Gallez B (2005) Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 11:743

    PubMed  CAS  Google Scholar 

  • Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83

    Article  PubMed  CAS  Google Scholar 

  • Baffert F, Thurston G, Rochon-Duck M, Le T, Brekken R, McDonald DM (2004) Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ Res 94:984

    Article  PubMed  CAS  Google Scholar 

  • Bang S, Hassan R, Pastan I (2005) Additive anti-tumor effect of Avastin and Immunotoxin combination therapy on tumor bearing mouse models. Proceedings of the 96th Annual Meeting, American Association for Cancer Research, abstract no. 4989

    Google Scholar 

  • Bottaro DP, Liotta LA (2003) Cancer: out of air is not out of action. Nature 423:593

    Article  PubMed  CAS  Google Scholar 

  • Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932

    Article  PubMed  CAS  Google Scholar 

  • Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329

    Article  PubMed  CAS  Google Scholar 

  • Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, Willett CG, Jain RK (2006) Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 24:1449

    Article  PubMed  CAS  Google Scholar 

  • Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group (2007) Sorafenib in advanced clearcell renal-cell carcinoma. N Engl J Med 356:125

    Article  PubMed  CAS  Google Scholar 

  • Fenton BM, Paoni SF, Ding I (2004) Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. Radiother Oncol 72:221

    Article  PubMed  CAS  Google Scholar 

  • Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391

    Article  PubMed  CAS  Google Scholar 

  • Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182

    Article  PubMed  CAS  Google Scholar 

  • Garber K (2002) Angiogenesis inhibitors suffer new setback. Nat Biotechnol 20:1067

    Article  PubMed  CAS  Google Scholar 

  • Gullino PM (1982) In: Gautherie M, Albert E (eds) Biomedical thermology. Liss, New York, pp 1–20

    Google Scholar 

  • Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandier A (2005) Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:2544

    Article  PubMed  CAS  Google Scholar 

  • Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O’Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL (2002) Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20:3804

    Article  PubMed  CAS  Google Scholar 

  • Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, Grone HJ, Debus J, Lipson KE, Abdollahi A (2005) Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65:3643

    Article  PubMed  CAS  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335

    Article  PubMed  CAS  Google Scholar 

  • Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM (2004) Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165:35

    PubMed  CAS  Google Scholar 

  • Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK (2002) Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416:279

    Article  PubMed  CAS  Google Scholar 

  • Jain RK (1999) Understanding barriers to drug delivery: high resolution in vivo imaging is key. Clin Cancer Res 5:1605

    PubMed  CAS  Google Scholar 

  • Jain RK (2001) Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987

    Article  PubMed  CAS  Google Scholar 

  • Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9:685

    Article  PubMed  CAS  Google Scholar 

  • Jain RK (2005a) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58

    Article  PubMed  CAS  Google Scholar 

  • Jain RK (2005b) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19 [Suppl]:7

    Google Scholar 

  • Jain RK, Safabakhsh N, Sckell A, Chen Y, Jiang P, Benjamin L, Yuan F, Keshet E (1998) Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 95:10820

    Article  PubMed  CAS  Google Scholar 

  • Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24

    Article  PubMed  CAS  Google Scholar 

  • Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727

    Article  PubMed  CAS  Google Scholar 

  • Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423

    Article  PubMed  CAS  Google Scholar 

  • Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM (2001) Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res 61:5491

    PubMed  CAS  Google Scholar 

  • Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792

    Article  PubMed  CAS  Google Scholar 

  • Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O’Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955

    Article  PubMed  CAS  Google Scholar 

  • Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115

    Article  PubMed  CAS  Google Scholar 

  • Murata R, Nishimura Y, Hiraoka M (1997) An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 37:1107

    Article  PubMed  CAS  Google Scholar 

  • Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, White E (2004) Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev 18:2095

    Article  PubMed  CAS  Google Scholar 

  • Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, and Jain RK (2004) Pathology: cancer cells compress intratumour vessels. Nature 427:695

    Article  PubMed  CAS  Google Scholar 

  • Ratner M (2004) Genentech discloses safety concerns over Avastin. Nat Biotechnol 22:1198

    Article  PubMed  CAS  Google Scholar 

  • Salnikov AV, Roswall P, Sundberg C, Gardner H, Heldin NE, Rubin K (2005) Inhibition of TGF-beta modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab Invest 85:512

    Article  PubMed  CAS  Google Scholar 

  • Sandier A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542

    Article  Google Scholar 

  • Segers J, Fazio VD, Ansiaux R, Martinive P, Feron O, Wallemacq P, Gallez B (2006) Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the ‘normalization’ window of the tumor vasculature. Cancer Lett 244:129–135

    Article  PubMed  CAS  Google Scholar 

  • Teicher BA (1996) A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-mechanism(s) of interaction). Cancer Metastasis Rev 15:247

    Article  PubMed  CAS  Google Scholar 

  • Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731

    Article  PubMed  CAS  Google Scholar 

  • Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE (2005) Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 65:1294

    Article  PubMed  CAS  Google Scholar 

  • Wildiers H, Guetens G, de Boeck G, Verbeken E, Landuyt B, Landuyt W, de Bruijn EA, van Oosterom AT (2003) Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88:1979

    Article  PubMed  CAS  Google Scholar 

  • Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145

    Article  PubMed  CAS  Google Scholar 

  • Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY (2005) Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23:8136

    Article  PubMed  Google Scholar 

  • Winkler F, Kozin SV, Tong R, Chae S, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Munn LL, Jain RK (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygénation, angiopoietin-1 and matrix metalloproteinases. Cancer Cell 6:553

    PubMed  CAS  Google Scholar 

  • Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, Madden T, McConkey D, Hicks M, Hess K, Charnsangavej CA, Abbruzzese JL (2004) A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs 22:459

    Article  PubMed  CAS  Google Scholar 

  • Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Steele Laboratory for Tumor Biology Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street Cox-734, Boston, MA, 02114, USA

    Rakesh K. Jain PhD & Dan G. Duda DMD, PhD

Authors
  1. Rakesh K. Jain PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dan G. Duda DMD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Tumorbiologie, Breisacher Str. 117, 79106, Freiburg i. Br., Germany

    Dieter Marmé PhD (Professor) (Professor)

  2. DKFZ, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany

    Norbert Fusenig MD (Professor, former Head of Division of Carcinogenesis and Differentiation) (Professor, former Head of Division of Carcinogenesis and Differentiation)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Jain, R.K., Duda, D.G. (2008). Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment. In: Marmé, D., Fusenig, N. (eds) Tumor Angiogenesis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-33177-3_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-33177-3_33

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-33176-6

  • Online ISBN: 978-3-540-33177-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation